ASCO 2023: Experts Recount the Biggest Surprises and Most Relevant Research
Experts met to debate recently presented trials in the hematologic oncology after the 2023 American Society of Clinical Oncology Annual Meeting.
Highlighting Mitigation Strategies for Toxicity in Follicular Lymphoma
Jennifer L. Garson, PA-C, gave an overview of follicular lymphoma and how she manages adverse effects in her institution.
Fruquintinib in the FRESCO-2 Trial
Arvind N. Dasari, MD, and Cathy Eng, MD, gave an overview on the use of fruquintinib in colorectal cancer.
Assessing Cytokine Release Syndrome After Treatment With Teclistamab in Multiple Myeloma
Thomas G. Martin, MD, discussed with his colleagues cytokine release syndrome after treatment with teclistamab for patients with multiple myeloma.
CONTACT-03: The “Most Important” Data Readout in RCC From the 2023 ASCO Annual Meeting
Robert Motzer, MD, led an expert panel to discuss the phase 3 CONTACT-03 which examined patients with renal cell carcinoma.
Acalabrutinib and Zanubrutinib Display Similar Efficacy Results in R/R CLL
Ryan Jacobs, MD, and Alan Pierre Zausner Skarbnik, MD, discussed the use of acalabrutinib and zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma
CancerNetwork hosted a Training Academy focused on sequencing therapies for patients with multiple myeloma who are treated with bispecific antibodies.
